Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) Equity Ratio (2022 - 2026)

Kura Oncology has reported Equity Ratio over the past 5 years, most recently at 0.17 for Q1 2026.

  • Quarterly Equity Ratio fell 66.26% to 0.17 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.17 through Mar 2026, down 66.26% year-over-year, with the annual reading at 0.24 for FY2025, 56.66% down from the prior year.
  • Equity Ratio was 0.17 for Q1 2026 at Kura Oncology, down from 0.24 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.93 in Q2 2023 and troughed at 0.17 in Q1 2026.
  • The 5-year median for Equity Ratio is 0.88 (2023), against an average of 0.68.
  • Year-over-year, Equity Ratio fell 1.71% in 2024 and then crashed 66.26% in 2026.
  • A 5-year view of Equity Ratio shows it stood at 0.92 in 2022, then dropped by 3.92% to 0.88 in 2023, then plummeted by 38.51% to 0.54 in 2024, then plummeted by 56.66% to 0.24 in 2025, then decreased by 29.9% to 0.17 in 2026.
  • Per Business Quant, the three most recent readings for KURA's Equity Ratio are 0.17 (Q1 2026), 0.24 (Q4 2025), and 0.37 (Q3 2025).